Pharvaris (NASDAQ:PHVS) Director Sells $1,089,968.88 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the transaction, the director directly owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total transaction of $241,424.40.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $33.86 on Friday. Pharvaris N.V. has a twelve month low of $17.05 and a twelve month high of $35.90. The company’s 50 day moving average is $31.07 and its 200 day moving average is $28.32. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -10.65 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. Sell-side analysts expect that Pharvaris N.V. will post -3.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently modified their holdings of PHVS. California State Teachers Retirement System lifted its position in shares of Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Pharvaris during the 4th quarter valued at approximately $35,000. Public Employees Retirement System of Ohio raised its stake in Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares during the period. Finally, Legal & General Group Plc raised its stake in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period.

Analysts Set New Price Targets

Several analysts recently commented on PHVS shares. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. UBS Group set a $74.00 target price on Pharvaris in a report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Finally, Morgan Stanley upped their price target on shares of Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research report on Thursday, June 25th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.64.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.